EN DE
Watch Palisade Bio Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Palisade Bio Inc (PALI) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Palisade Bio Inc stock $0.63, price $1.13, that is 44.3% below the price, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PB Palisade Bio Inc logo Thin data Nov 6, 2026

Palisade Bio Inc

PALI · US
Very expensive, weak quality

Our calculation puts a fair price 44% below what the stock costs today.

Costs just 1.9 times its yearly profit.
Quality 42/100
Mixed vs. peers (4/7)
Insiders bought $278,900 (6M) · sold $410,226
Fair value $0.6290 · Strongly overvalued
Weak Growth (revenue 5y −0.8 %/yr in USD)
Negative free cash flow
Narrow moat 6/100 · thin data
Thin data
⚠ Dilution
Watch Palisade Bio Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$2,250 $0.5400 Fair Value $0.6290 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $0.5400 – $2,250 · fair‑value band $0.4165 – $0.7905 · the $1.13 price screens above the $0.6290 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Palisade Bio in your weekly email

Every Wednesday you see whether Palisade Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.

Show moreShow less

Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.

The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Stock analysis

Palisade Bio Inc (PALI) currently trades at $1.13, while our model-based Fair Value estimate is $0.6290, 44% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.4165 (bear) to $0.7905 (bull), the price of $1.13 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Palisade Bio Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$16.8M in FY2025.

Key figures

Market cap $239M Micro · P/E ratio 1.9 · EPS (TTM) $0.6000 · Return on equity −51.4% · Return on assets (EBIT) −135% (5-year average) · Operating margin −2,340% · Revenue (TTM) $500K · Free cash flow −$10.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 60% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −44%, PALI screens richer than that median.

Fair Value models

Bear $0.4165 Fair Value $0.6290 Bull $0.7905
Price $1.13 · Downside -44.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.5145 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.4900 $0.7400 $0.9300 52
All 1 models by family
Asset-Based
NCAV (Graham) $0.4900 $0.7400 $0.9300 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 55
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 7
How calm the share price moves, does not count
Price momentum 7
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors bought shares worth $278,900, most recently on Oct 2, 2026. Over the same period, 2 people sold shares worth $410,226. Buying cluster

  • BuyDonald Allen WilliamsDirector3× since Jan 9, 2026: 30,000 shares, avg. $1.55$46,550Oct 2, 2026
  • BuyRobert Baltera Jr.Director3× since Jul 1, 2026: 125,000 shares, avg. $2.00$250,100Jul 9, 2026
  • SaleJohn David FinleyCEO, CFO, Director2× since Feb 12, 2026: 150,694 shares, avg. $2.06$310,690Jul 7, 2026
  • SaleMitchell Lawrence JonesChief Medical Officer2× since Feb 12, 2026: 53,869 shares, avg. $2.04$109,835Jul 7, 2026

Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+164.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.8%
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,176.5% (2018) → −5,228.0% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PALI screens overvalued: fair value 44% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Palisade Bio Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside −44.3% · Above median
Profitability
Return on assets −12.5% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 1.9× · Cheapest 25%
P/B 1.85× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs PALI
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs PALI
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs PALI
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs PALI
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs PALI
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs PALI
argenx SE ARGX $927.21 $908.40 −2% vs PALI
CSL Limited CSL A$200.77 A$183.04 −9% vs PALI
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs PALI
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs PALI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Palisade Bio Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Palisade Bio Inc Fair Value". https://www.fairvalue-calculator.com/stock/PALI

Frequently asked questions

Is Palisade Bio Inc (PALI) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $0.6290 versus a price of $1.13, about 44% lower (overvalued).
What is the fair value of PALI?
Our model-based fair value for Palisade Bio Inc is $0.6290 (as of Nov 6, 2026), built from audited fundamentals. The current price: $1.13.
What is the quality score of PALI?
Palisade Bio Inc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Palisade Bio Inc (PALI)?
Our model-based price target is the fair value of $0.6290 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario $0.4165, optimistic scenario $0.7905. It is a calculation from audited fundamentals, not an analyst target.
What is the Palisade Bio Inc stock forecast for 2026?
Our models put fair value at $0.6290, about 44% lower versus a price of $1.13 (overvalued). Cautious scenario $0.4165, optimistic scenario $0.7905. The calculation is refreshed regularly with new filings.
What is the revenue of Palisade Bio Inc (PALI)?
Palisade Bio Inc reported trailing-twelve-month revenue of about $500K (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Palisade Bio Inc (PALI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Palisade Bio Inc it is $0.6290 per share (as of Nov 6, 2026), against a price of $1.13. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Palisade Bio Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, PALI trades above its calculated fair value: price $1.13, fair value $0.6290, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PALI?
No. The price is what the market pays today ($1.13); the fair value is what the company's own numbers justify ($0.6290). For Palisade Bio Inc the two are $0.5010 per share apart. That gap is exactly why we show both numbers side by side.
How much is Palisade Bio Inc worth?
The market values Palisade Bio Inc at about $239M (market capitalisation, as of Nov 6, 2026). Per share that is $1.13; our models calculate a fair value of $0.6290 per share.
What do the bullish and bearish scenarios say about PALI?
Our models span a range for Palisade Bio Inc: cautious scenario $0.4165, base $0.6290, optimistic $0.7905 per share (as of Nov 6, 2026, price $1.13). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PALI?
Palisade Bio Inc trades at a price-to-earnings ratio of 1.9 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.6290 is built from several models across several years. Other multiples: P/B 1.9.
How solid is the balance sheet of Palisade Bio Inc (PALI)?
Balance-sheet figures for Palisade Bio Inc (as of Nov 6, 2026): return on equity −51.4%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is PALI from its 52-week high?
Palisade Bio Inc trades at $1.13, about 60% below its 52-week high of $2.80 and 1% above the low of $1.12 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6290 is for.
Which stocks are comparable to Palisade Bio Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Palisade Bio Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $1.13, calculated fair value $0.6290 (−44%), Quality Score 42/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PALI calculated?
We run Palisade Bio Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.6290 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Palisade Bio Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Palisade Bio Inc (PALI)?
The closing price on Nov 6, 2026 was $1.13. Our model-based fair value is $0.6290, about 44% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Palisade Bio Inc right now?
The price sits above even our optimistic bull case ($0.7905). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.4165 to $0.7905) leaves room in how you read the outcome.

Key figures of Palisade Bio Inc

How large is the market capitalisation of Palisade Bio Inc (PALI)?
The market capitalisation of Palisade Bio Inc is $239M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Palisade Bio Inc (PALI)?
Earnings per share at Palisade Bio Inc are $0.6000 (price ÷ EPS = P/E 1.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Palisade Bio Inc (PALI)?
The return on equity (ROE) of Palisade Bio Inc is −51.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Palisade Bio Inc (PALI)?
On an EBIT basis the return on assets of Palisade Bio Inc is −135% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Palisade Bio Inc (PALI)?
The operating margin of Palisade Bio Inc is −2,340% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Palisade Bio Inc (PALI) generate?
The free cash flow of Palisade Bio Inc is −$10.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Palisade Bio Inc (PALI) hold?
Palisade Bio Inc holds more cash than debt, $133M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Palisade Bio Inc in the live analysis

One click puts Palisade Bio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.